MIAMI, Dec. 05, 2016 -- UBS Financial Services Inc. and UBS Financial Services Inc. of Puerto Rico (collectively “UBS”) were slammed with an $18 million FINRA arbitration verdict (Case No. 14-02464) released today, says Sonn and Erez PLC. The award included approximately $12.7 million in compensatory damages, $2.5 million in interest, $3.18 million in attorneys fees, and $163,000 in expert costs. The arbitration, like over 1,000 other arbitrations, centered on the sale of Puerto Rico Municipal Bonds and Puerto Rico closed end funds that owned Puerto Rico muni bonds on margin.
“This verdict supports our theory that UBS oversold Puerto Rico bonds and closed end funds to their customers, in concentrated amounts, like many other brokerage firms in Puerto Rico,” said Jeffrey Sonn of Sonn & Erez, PLC, whose law firm was not involved in the verdict, but who represent over 200 Puerto Rico investors with similar claims. “Our firm has already won two large Puerto Rico arbitration awards against UBS, and resolved many, many other claims similar to today’s verdict,” added Sonn.
“Brokerage firms in Puerto Rico, like UBS, in our opinion, placed too much emphasis on the triple tax free benefits of the Puerto Rico muni bonds and closed end funds, and failed to properly supervise the concentration in customer accounts, which left many customers with a majority, and in some cases, all of their money invested in just Puerto Rico muni bonds and proprietary closed end bond funds,” added Jeff Erez, Esq. of Sonn and Erez.
In 2015, FINRA fined UBS $18.5 million finding that “UBS PR failed to monitor the combination of leverage and concentration levels in customer accounts to ensure that the transactions were suitable given the customers' risk objectives and profiles,” according to FINRA.
Sonn and Erez, along with the Puerto Rico-based law firm of Aldarondo & Lopez Bras, represent over 200 customers that have significant losses in Puerto Rico muni bonds and proprietary closed end bond funds.
UBS Puerto Rico bond funds include:
- Tax-Free Puerto Rico Fund I-II,
- Tax-Free Puerto Rico Target Maturity Fund,
- Puerto Rico AAA Portfolio Target Maturity Fund,
- Puerto Rico AAA Portfolio Bond Fund I-II,
- Puerto Rico GNMA & U.S. Government Target Maturity Fund,
- Puerto Rico Mortgage-Backed & U.S. Government Securities Fund,
- Puerto Rico Fixed Income Fund I-VI,
- Puerto Rico Investors Tax-Free Fund I-VI,
- Puerto Rico Tax-Free Target Maturity Fund I-II,
- Puerto Rico Investors Bond Fund.
Sonn & Erez PLC is a nationally leading law firm that represents individual and institutional investors in a wide variety of investment and securities cases. Our co-counsel, Aldarondo & Lopez-Bras is a leading law firm in Guaynabo, Puerto Rico, also representing investors.
For more information: Miami - Jeffrey Sonn, Esq. or Jeffrey Erez, Esq. (305) 428-8530. Puerto Rico – Eliezer Aldarondo-Lopez, Esq. (787) 474-5457


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



